Understanding how genetics affect dosing of a medication for children with movement disorders.
Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children with Dystonia and Cerebral Palsy
This study is looking at how kids with cerebral palsy process the medication Trihexyphenidyl differently based on their genes, so we can find the best dose for each child and make their treatment safer and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Mercy Hosp (Kansas City, Mo) NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11052990 on NIH RePORTER |
What this research studies
This research focuses on developing a precision dosing model for Trihexyphenidyl, a medication used to treat dystonia in children with cerebral palsy. The study aims to understand how genetic differences among children can influence how they metabolize this medication, which could lead to more effective and safer treatment options. By investigating pharmacogenomic factors, the research seeks to minimize side effects and improve therapeutic outcomes for young patients. The ultimate goal is to establish a standardized dosing approach that can be used in clinical trials and everyday practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with dystonia associated with cerebral palsy.
Not a fit: Patients who do not have dystonia or cerebral palsy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for children suffering from dystonia and cerebral palsy.
How similar studies have performed: Previous research has shown promise in using pharmacogenomic approaches to optimize medication dosing, indicating potential for success in this novel application.
Where this research is happening
Kansas City, United States
- Children's Mercy Hosp (Kansas City, Mo) — Kansas City, United States (Active)
Researchers
- Principal investigator: Gelineau-Morel, Rose Nicole — Children's Mercy Hosp (Kansas City, Mo)
- Study coordinator: Gelineau-Morel, Rose Nicole
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.